Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesGreen tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors
Blood, 02/12/09
Golden EB et al. - Results indicate that green tea polyphenols may have the potential to negate the therapeutic efficacy of bortezomib and suggest that consumption of green tea products may be contraindicated during cancer therapy with bortezomib.
Related Articles
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma
Blood, 11/02/09
Relevance Score: 89%
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Annals of Oncology, 10/30/09
Relevance Score: 89%
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology, 10/02/09
Relevance Score: 89%
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology, 10/01/09
Relevance Score: 89%
VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III Vista study
Journal of Clinical Oncology, 10/29/09
Relevance Score: 87%
Today in Alternative Therapies...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy of Goshajinkigan for Peripheral Neurotoxicity of Oxaliplatin in Patients with Advanced or Recurrent Colorectal Cancer
Evidence-based Complementary and Alternative Medicine , 12/02/09
Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3
Carcinogenesis, 12/01/09
A phase 2 trial exploring the effects of high-dose (10,000 IU/day) Vitamin D3 in breast cancer patients with bone metastases
Cancer, 11/18/09
Sponsor
Article Search
Sponsor
Sponsor